Search results
Showing 901 to 915 of 2548 results for methods
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
In development Reference number: GID-HTE10011 Expected publication date: TBC
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.
In development Reference number: GID-QS10186 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Autism spectrum disorder in under 19s: support and management (CG170)
This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.
This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.
View quality statements for QS135Show all sections
Sections for QS135
- Quality statements
- Quality statement 1: Providing information about potential signs and symptoms of preterm labour
- Quality statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage
- Quality statement 3: Information for women having a planned preterm birth
- Quality statement 4: Tocolysis for women between 26+0 and 33+6 weeks of pregnancy
- Quality statement 5: Corticosteroids for women between 24+0 and 33+6 weeks of pregnancy
- Quality statement 6: Magnesium sulfate for women between 24+0 and 29+6 weeks of pregnancy
- Update information
is considered to be adequate for the majority of pressure ulcers, other methods, including mechanical, enzymatic, sharp debridement and...
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
In development Reference number: GID-TA10868 Expected publication date: 15 July 2026
In development Reference number: GID-TA11201 Expected publication date: 11 February 2026
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]
In development Reference number: GID-TA11662 Expected publication date: 11 February 2026
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.